MGNX Macrogenics Inc
Price (delayed)
$2.76
Market cap
$173.23M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.58
Enterprise value
$27.7M
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its
Highlights
The EPS has grown by 28% from the previous quarter
MGNX's net income is up by 28% QoQ
Macrogenics's equity has surged by 108% QoQ but it has decreased by 38% YoY
The quick ratio rose by 40% QoQ but it fell by 36% YoY
Key stats
What are the main financial stats of MGNX
Market
Valuations
Earnings
Shares outstanding
62.76M
Market cap
$173.23M
Enterprise value
$27.7M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.44
Price to sales (P/S)
1.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.2
Revenue
$141.33M
Gross profit
$134.36M
Operating income
-$107.09M
Net income
-$97.62M
EBIT
-$96.48M
EBITDA
-$86.47M
Free cash flow
-$61.55M
Per share
Balance sheet
Liquidity
EPS
-$1.58
EPS diluted
-$1.58
Free cash flow per share
-$0.98
Book value per share
$1.91
Revenue per share
$2.25
TBVPS
$4.22
Total assets
$264.49M
Total liabilities
$144.43M
Debt
$34.1M
Equity
$120.07M
Working capital
$162.89M
Debt to equity
0.28
Current ratio
3.75
Quick ratio
3.53
Net debt/EBITDA
1.68
Margins
Efficiency
Dividend
EBITDA margin
-61.2%
Gross margin
95.1%
Net margin
-69.1%
Operating margin
-75.8%
Return on assets
-38.6%
Return on equity
-89.4%
Return on invested capital
-81.3%
Return on capital employed
-47%
Return on sales
-68.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MGNX stock price
How has the Macrogenics stock price performed over time
Intraday
-4.17%
1 week
7.81%
1 month
-8%
1 year
-83.8%
YTD
-15.08%
QTD
-15.08%
Financial performance
How have Macrogenics's revenue and profit performed over time
Revenue
$141.33M
Gross profit
$134.36M
Operating income
-$107.09M
Net income
-$97.62M
Gross margin
95.1%
Net margin
-69.1%
Macrogenics's operating margin has surged by 84% QoQ and by 14% YoY
MGNX's net margin has surged by 79% since the previous quarter
The company's operating income rose by 46% QoQ
MGNX's net income is up by 28% QoQ
Growth
What is Macrogenics's growth rate over time
Valuation
What is Macrogenics stock price valuation
P/E
N/A
P/B
1.44
P/S
1.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.2
The EPS has grown by 28% from the previous quarter
Macrogenics's equity has surged by 108% QoQ but it has decreased by 38% YoY
The P/B is 69% below the last 4 quarters average of 4.7 and 61% below the 5-year quarterly average of 3.7
The price to sales (P/S) is 87% lower than the last 4 quarters average of 9.8 and 86% lower than the 5-year quarterly average of 8.8
The revenue has increased by 17% YoY
Efficiency
How efficient is Macrogenics business performance
The ROS has soared by 79% from the previous quarter
MGNX's ROA is up by 23% from the previous quarter
MGNX's return on equity is up by 16% since the previous quarter
MGNX's ROIC is up by 2.6% QoQ
Dividends
What is MGNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MGNX.
Financial health
How did Macrogenics financials performed over time
The total assets is 83% more than the total liabilities
The quick ratio rose by 40% QoQ but it fell by 36% YoY
MGNX's current ratio is up by 38% since the previous quarter but it is down by 34% year-on-year
MGNX's debt is 72% smaller than its equity
Macrogenics's equity has surged by 108% QoQ but it has decreased by 38% YoY
The debt to equity has surged by 56% year-on-year but it has dropped by 53% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.